NCT02773381View on ClinicalTrials.gov

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 2, 2016

Primary Completion Date

October 19, 2018

Study Completion Date

October 19, 2018

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

semaglutide

Oral administration once-daily.

DRUG

placebo

Oral administration once-daily.

Trial Locations (1)

LS2 9LH

Novo Nordisk Investigational Site, Leeds

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY